/ Suven Life Sciences Gets Product Patent Stocks Up By 2% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 23 January 2017

Suven Life Sciences, a leading bio-pharma company has received a patent for its product in Australia, pertaining to the treatment of disorders which are associated with Neurodegenerative diseases. The said patent which the company has received is valid through 2033.

Now, the company has 25 patents from Australia including the current patent; 3 clinical stage compounds; and it also has 10 therapeutic drug candidates. The stock is trading with gains, above its 30 day SMA. Earlier, this year, it had received patent for one of its products from Eurasia and one from Norway. The company now holds 20 patents from Eurasia and six from Norway. 

Suven Life Sciences Ltd is currently trading at Rs 172.45, up by Rs 2.25 or 1.32% from its previous closing of Rs 170.2 on the BSE. The scrip opened at Rs 171.7 and has touched a high and low of Rs 178.4 and Rs 170.7 respectively. So far 57483(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2166.35 crore.

The BSE group 'B' stock of face value Rs 1 has touched a 52 week high of Rs 228.5 on 30-May-2016 and a 52 week low of Rs 144.35 on 19-Feb-2016. Last one week high and low of the scrip stood at Rs 178.7 and Rs 169.5 respectively.

The promoters holding in the company stood at 60 % while Institutions and Non-Institutions held 7.32 % and 32.68 % respectively. The stock is currently trading below its 200 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717